A Phase 3 interventional study of Tucatinib and Trastuzumab in HER2 Positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 307 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.
Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 5 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 5 of the 18 other live ones, and was the 19th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Institut Curie · Sites in France
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Institut Curie · Sites in France
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tucatinib is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 22 · Phase 3 3
First in 2010; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 654 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 41 across the 31 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 10th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2022, is one of 25 in phase 3, reaches primary completion later than 5 of the 25 other live ones, and was the 138th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
5 of the studies testing tucatinib in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
| NCT05458674Criterium, Inc.Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | 2027-06-01 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing tucatinib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in.
All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days
Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days
Trastuzumab and pertuzumab will be administered as follows:
AND
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have unresectable locally advanced or disease.
CNS Inclusion - Based on screening contrast-enhanced brain magnetic resonance imaging (MRI), participants may have any of the following:
Previously treated brain metastases which are asymptomatic
Exclusion Criteria:
CNS Exclusion - Based on screening brain MRI and clinical assessment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tucatinib + trastuzumab + pertuzumab
Drug: Tucatinib · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Combination product: Trastuzumab + Pertuzumab
Placebo + trastuzumab + pertuzumab
Drug: Trastuzumab · Drug: Pertuzumab · Drug: Combination product: Trastuzumab + Pertuzumab · Drug: Placebo
300mg given by mouth (orally) twice daily
Also known as: TUKYSA, ONT-380, ARRY-380
6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
Also known as: Herceptin, Herceptin Hylecta
420mg given by IV every 21 days
Also known as: Perjeta
Drug pages: Trastuzumab · Pertuzumab
600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
Also known as: Phesgo
Given orally twice daily
Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
PFS: time from randomization to the first documented disease progression (PD) (as assessed by investigator per RECIST 1.1) or death from any cause, whichever occurred first. PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum of diameter recorded since the treatment started or the appearance of 1 or more new lesions. Participants without documentation of PD/ death at the time of analysis, were censored at date of last tumor assessment with an overall response of complete response (CR), partial response (PR), stable disease (SD), non-CR/non-PD or no evidence of disease (NED). CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Overall Survival (OS)
OS: time from randomization to death due to any cause. For a participant who would not known to have died by the end of study follow-up, observation of OS would be censored on the date the participant was last known to be alive (i.e., the date of last contact).
Time frame: From the date of randomization until date of death or censoring date (approximately 66.7 months)
PFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1
PFS per BICR was defined as the time from the date of randomization to the documented disease progression assessed by BICR according to RECIST v1.1 or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>=20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Time to Deterioration (TTD) of Health-Related Quality of Life (HRQoL)
Time to deterioration of HRQoL was defined as time to 10-point decrease in the global health status/QoL scale of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30). EORTC QLQ-C30 is 30 item questionnaires composed of 5 multi-item functional domains (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, nausea, and vomiting) and 6 single items for symptoms (shortness of breath, loss of appetite, sleep disturbance, constipation, diarrhea and financial impact of the disease), 2 global items (health, overall QoL). Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.
Time frame: Approximately 66.7 months
Central Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1
CNS-PFS was defined as the time from randomization to investigator assessed disease progression in brain according to RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>= 20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death at the time of analysis were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both Serious AE (SAEs) and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months)
Number of Participants With Treatment Emergent Laboratory Abnormalities
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Treatment emergent laboratory abnormalities include: hematology (hemoglobin decreased, hemoglobin increased, leukocytes decreased, neutrophils decreased, platelets decreased); chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, creatinine increased, potassium decreased, potassium increased, sodium decreased, sodium increased, total bilirubin increased).
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
Number of Participants With TEAEs Leading to Dose Discontinuations
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose discontinuations with study treatment will be reported.
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
Number of Participants With TEAEs Leading to Dose Hold
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose hold with study treatment will be reported. Dose hold requirements are defined per protocol.
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
Number of Participants With TEAEs Leading to Dose Reductions
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose reductions with tucatinib, trastuzumab and pertuzumab are reported. Dose reduction requirements are defined per protocol.
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
Trough Concentration (Ctrough) of Tucatinib
Concentration at Trough was defined as predose/trough concentration observed directly from data.
Time frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 5 and 6
Number of Participants With TEAEs: Through Study Completion
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both SAEs and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
| Milestone | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| Started | 326 | 328 |
| Intent-to-treat (itt) analysis set | 326 | 328 |
| Safety analysis set (sas) | 326 | 324 |
| Completed | 0 | 0 |
| Not completed | 326 | 328 |
| Withdrew: Death | 18 | 33 |
| Withdrew: Withdrawal by subject | 9 | 4 |
| Withdrew: Ongoing | 299 | 291 |
PFS: time from randomization to the first documented disease progression (PD) (as assessed by investigator per RECIST 1.1) or death from any cause, whichever occurred first. PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum of diameter recorded since the treatment started or the appearance of 1 or more new lesions. Participants without documentation of PD/ death at the time of analysis, were censored at date of last tumor assessment with an overall response of complete response (CR), partial response (PR), stable disease (SD), non-CR/non-PD or no evidence of disease (NED). CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
| Months | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | 24.9 (21.3 to NA) | 16.3 (12.6 to 18.7) |
OS: time from randomization to death due to any cause. For a participant who would not known to have died by the end of study follow-up, observation of OS would be censored on the date the participant was last known to be alive (i.e., the date of last contact).
Results for this outcome have not been posted.
PFS per BICR was defined as the time from the date of randomization to the documented disease progression assessed by BICR according to RECIST v1.1 or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>=20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
| Months | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| PFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 | 28.9 (24.3 to NA) | 16.0 (12.3 to 22.9) |
Time to deterioration of HRQoL was defined as time to 10-point decrease in the global health status/QoL scale of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30). EORTC QLQ-C30 is 30 item questionnaires composed of 5 multi-item functional domains (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, nausea, and vomiting) and 6 single items for symptoms (shortness of breath, loss of appetite, sleep disturbance, constipation, diarrhea and financial impact of the disease), 2 global items (health, overall QoL). Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.
Results for this outcome have not been posted.
CNS-PFS was defined as the time from randomization to investigator assessed disease progression in brain according to RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>= 20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death at the time of analysis were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.
| Months | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| Central Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1 | NA (NA to NA) | NA (NA to NA) |
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both Serious AE (SAEs) and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
| Participants | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 323 | 313 |
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Treatment emergent laboratory abnormalities include: hematology (hemoglobin decreased, hemoglobin increased, leukocytes decreased, neutrophils decreased, platelets decreased); chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, creatinine increased, potassium decreased, potassium increased, sodium decreased, sodium increased, total bilirubin increased).
Results for this outcome have not been posted.
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose discontinuations with study treatment will be reported.
Results for this outcome have not been posted.
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose hold with study treatment will be reported. Dose hold requirements are defined per protocol.
Results for this outcome have not been posted.
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose reductions with tucatinib, trastuzumab and pertuzumab are reported. Dose reduction requirements are defined per protocol.
Results for this outcome have not been posted.
Concentration at Trough was defined as predose/trough concentration observed directly from data.
| nanograms per milliliter | Tucatinib + Trastuzumab + Pertuzumab |
|---|---|
| Cycle 2 | 151.83 ± 180.04 |
| Cycle 3 | 158.63 ± 144.77 |
| Cycle 4 | 137.0 ± 192.19 |
| Cycle 5 | 155.4 ± 180.92 |
| Cycle 6 | 146.03 ± 215.17 |
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both SAEs and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Results for this outcome have not been posted.
Collected over From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tucatinib + Trastuzumab + Pertuzumab | 18/326 (5.5%) | 55/326 (16.9%) | 323/326 (99.1%) |
| Placebo + Trastuzumab + Pertuzumab | 33/328 (10.1%) | 26/324 (8%) | 313/324 (96.6%) |
| Event | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 5/326 | 0/324 |
| Drug-induced liver injuryHepatobiliary disorders | 4/326 | 0/324 |
| DiarrhoeaGastrointestinal disorders | 3/326 | 0/324 |
| Urinary tract infectionInfections and infestations | 0/326 | 2/324 |
| Wound infectionInfections and infestations | 0/326 | 2/324 |
| SeizureNervous system disorders | 1/326 | 2/324 |
| Cardiac failureCardiac disorders | 2/326 | 1/324 |
| Liver injuryHepatobiliary disorders | 2/326 | 0/324 |
| BacteraemiaInfections and infestations | 2/326 | 0/324 |
| CellulitisInfections and infestations | 2/326 | 1/324 |
| Event | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 237/326 | 166/324 |
| NauseaGastrointestinal disorders | 107/326 | 76/324 |
| Alanine aminotransferase increasedInvestigations | 90/326 | 23/324 |
| Aspartate aminotransferase increasedInvestigations | 82/326 | 29/324 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 67/326 | 75/324 |
| FatigueGeneral disorders | 67/326 | 41/324 |
| VomitingGastrointestinal disorders | 64/326 | 45/324 |
| PruritusSkin and subcutaneous tissue disorders | 62/326 | 58/324 |
| HeadacheNervous system disorders | 61/326 | 57/324 |
| CoughRespiratory, thoracic and mediastinal disorders | 60/326 | 45/324 |
| Age, Continuous(Years) | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Mean | 53.2 ± 11.5 | 53.2 ± 11.0 | 53.2 ± 11.3 |
| Sex: Female, Male(Participants) | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Female | 326 | 328 | 654 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| White | 147 | 147 | 294 |
| Asian | 119 | 111 | 230 |
| Not reportable | 39 | 40 | 79 |
| Black or African American | 10 | 9 | 19 |
| Other | 5 | 8 | 13 |
| Unknown | 1 | 6 | 7 |
| Multiple | 5 | 1 | 6 |
| American Indian or Alaska Native | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Tucatinib + Trastuzumab + Pertuzumab | Placebo + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Not Hispanic, Latino/a, or of Spanish Origin | 221 | 212 | 433 |
| Hispanic, Latino/a, or of Spanish Origin | 55 | 71 | 126 |
| Not reportable | 39 | 41 | 80 |
| Unknown | 11 | 4 | 15 |
Showing the first 100 of 307 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2022 to primary completion in Sep 2025, 41 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 41 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib
Seagen, a wholly owned subsidiary of Pfizer →